Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

Item

http://www.wikidata.org/entity/Q41892226

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

@en

type

Item

label

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

@en

prefLabel

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

@en

P1476

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

@en

P2093

Alberto Grossi

http://www.w3.org/2001/XMLSchema#string

Francesca Balestri

http://www.w3.org/2001/XMLSchema#string

Simone Santini

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin or Darbepoetin for patients with cancer

Development and characterization of novel erythropoiesis stimulating protein (NESP)

Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

P304

269-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.2007.3.2.269

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5491032

http://www.w3.org/2001/XMLSchema#string

P698

18360635

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

P932

1936308

http://www.w3.org/2001/XMLSchema#string